A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are an oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs, enabled by our proprietary integrated cell-free protein synthesis platform, XpressCF®, and our site-specific conjugation platform, XpressCF+®. We aim to design and develop therapeutics using the most relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, or iADCs, and dual conjugate ADCs, or ADC2s. Our molecules are directed primarily against clinically validated targets where the current standard of care is suboptimal. We believe that our platform allows us to accelerate the discovery and development of potential first-in-class and/or best-in-class molecules by enabling the rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates. Our mission is to transform the lives of patients by creating medicines with improved therapeutic profiles for areas of unmet need.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 106M | - | 154M | 68M | 62M | 43M |
| Net Income | -217M | -227M | -107M | -119M | -106M | -32M |
| EPS | $-26.00 | $-29.60 | $-17.80 | $-23.50 | $-22.90 | $-9.90 |
| Free Cash Flow | 0 | -192M | -112M | 3.3M | -82M | -68M |
| ROIC | -69.9% | -422.4% | -71.4% | -54.0% | -39.3% | -9.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 7.68 | 2.15 | 0.02 | 0.06 | 0.07 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -186M | -238M | -89M | -129M | -99M | -71M |
| Operating Margin | -175.7% | - | -58.1% | -190.3% | -159.2% | -166.3% |
| ROE | 0.0% | -234.2% | -71.4% | -54.9% | -41.8% | -9.7% |
| Shares Outstanding | 85M | 8M | 6M | 5M | 5M | 3M |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 52M | 38M | 43M | 43M | 62M | 68M | 154M | N/A | 106M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -19M | -37M | -55M | -71M | -99M | -129M | -89M | -238M | -186M |
| Op. Margin | -37.2% | -96.9% | -129.8% | -166.3% | -159.2% | -190.3% | -58.1% | N/A | -175.7% |
| Net Income | N/A | -35M | -56M | -32M | -106M | -119M | -107M | -227M | -217M |
| Net Margin | N/A | -91.9% | -130.4% | -75.2% | -170.6% | -175.9% | -69.5% | N/A | -205.2% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||
| ROIC | N/A | -25.0% | -52.3% | -9.0% | -39.3% | -54.0% | -71.4% | N/M | -69.9% |
| ROE | N/A | -26.8% | -57.0% | -9.7% | -41.8% | -54.9% | -71.4% | -234.2% | 0.0% |
| ROA | N/A | -15.8% | -35.6% | -8.2% | -30.9% | -29.3% | -22.7% | -53.0% | -103.4% |
| Cash Flow | |||||||||
| Op. Cash Flow | -37M | 13M | -65M | -68M | -82M | 3.5M | -112M | -192M | -223M |
| Free Cash Flow | -40M | 12M | -65M | -68M | -82M | 3.3M | -112M | -192M | 0 |
| Owner Earnings | -43M | 5.3M | -80M | -84M | -110M | -28M | -143M | -223M | -254M |
| CapEx | 3.3M | 205K | 270K | 546K | 370K | 280K | 214K | 673K | 0 |
| Maint. CapEx | 5.0M | 4.5M | 4.8M | 4.3M | 4.8M | 5.7M | 6.8M | 7.2M | 7.2M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 5.0M | 4.5M | 4.8M | 4.3M | 4.8M | 5.7M | 6.8M | 7.2M | 7.2M |
| CapEx/OCF | N/A | 1.6% | N/A | N/A | N/A | 7.9% | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 7K | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.4M | 2.9M | 10M | 12M | 23M | 26M | 25M | 25M | 25M |
| Debt Repayment | 170K | 0 | 5.0M | 10M | 0 | 9.4M | 13M | 4.1M | 4.1M |
| Balance Sheet | |||||||||
| Net Debt | N/A | -194M | -109M | -302M | -145M | -299M | N/A | N/A | -168M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 168M |
| Long-Term Debt | N/A | 10M | 8.9M | 25M | 16M | 3.8M | N/A | N/A | N/A |
| Debt/Equity | -1.37 | 0.08 | 0.09 | 0.07 | 0.06 | 0.02 | 2.15 | 7.68 | 0.00 |
| Interest Coverage | -31.5 | -29.2 | -52.9 | -42.4 | -48.2 | -69.0 | -7.1 | -7.7 | -7.7 |
| Equity | -109M | 132M | 98M | 332M | 253M | 217M | 150M | 45M | -87M |
| Total Assets | 41M | 223M | 156M | 394M | 341M | 407M | 471M | 387M | 210M |
| Total Liabilities | 150M | 92M | 59M | 62M | 89M | 190M | 321M | 343M | 35M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -115M | -150M | -196M | -228M | -333M | -453M | -559M | -787M | -787M |
| Working Capital | -6.3M | 174M | 96M | 349M | 177M | 287M | 328M | 211M | 211M |
| Current Assets | 26M | 210M | 129M | 378M | 219M | 353M | 422M | 343M | 343M |
| Current Liabilities | 32M | 36M | 33M | 30M | 42M | 67M | 94M | 132M | 132M |
| Per Share Data | |||||||||
| EPS | -439.50 | -61.30 | -24.30 | -9.90 | -22.90 | -23.50 | -17.80 | -29.60 | -26.00 |
| Owner EPS | -18.95 | 2.28 | -34.92 | -25.89 | -23.82 | -5.61 | -23.89 | -29.08 | -2.99 |
| Book Value | -47.55 | 56.95 | 42.63 | 102.32 | 54.80 | 42.79 | 24.94 | 5.80 | -1.03 |
| Cash Flow/Share | -16.17 | 5.49 | -28.34 | -20.89 | -17.72 | 0.70 | -18.60 | -24.93 | -2.46 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 2.3M | 2.3M | 2.3M | 3.2M | 4.6M | 5.1M | 6.0M | 7.7M | 85.1M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1.1 |
| P/FCF | N/A | 16.1 | N/A | N/A | N/A | 110.6 | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 1.5 | 2.6 | 2.1 | 2.8 | 1.7 | 1.7 | 3.3 | N/A |
| Price/Sales | N/A | 7.3 | 5.6 | 8.7 | 15.0 | 5.3 | 1.9 | N/A | 23.2 |
| FCF Yield | N/A | 6.2% | -25.9% | -9.6% | -11.5% | 0.9% | -42.8% | -132.3% | N/A |
| Market Cap | N/A | 201M | 252M | 711M | 713M | 362M | 262M | 145M | 2.5B |
| Avg. Price | N/A | 122.11 | 104.38 | 114.19 | 201.02 | 71.04 | 47.43 | 38.46 | 28.78 |
| Year-End Price | N/A | 86.90 | 109.80 | 219.10 | 154.70 | 71.30 | 43.60 | 18.90 | 28.78 |
SUTRO BIOPHARMA, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
SUTRO BIOPHARMA, INC. (STRO) has a 5-year average return on invested capital (ROIC) of -43.4%. This is below average and may indicate limited pricing power.
SUTRO BIOPHARMA, INC. (STRO) has a market capitalization of $2.5B. It is classified as a mid-cap stock.
SUTRO BIOPHARMA, INC. (STRO) does not currently pay a regular dividend.
SUTRO BIOPHARMA, INC. (STRO) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
SUTRO BIOPHARMA, INC. (STRO) generated $-192 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
SUTRO BIOPHARMA, INC. (STRO) has a debt-to-equity ratio of 7.68. This indicates higher leverage, which may increase financial risk.
SUTRO BIOPHARMA, INC. (STRO) reported earnings per share (EPS) of $-29.60 in its most recent fiscal year.
SUTRO BIOPHARMA, INC. (STRO) has a return on equity (ROE) of -234.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 8 years of financial data for SUTRO BIOPHARMA, INC. (STRO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SUTRO BIOPHARMA, INC. (STRO) has a book value per share of $5.80, based on its most recent annual SEC filing.